GSK plc (GSK)
NYSE · Healthcare · Drug Manufacturers - General
$46.55−1.02%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $93.3B
- P/E (trailing)
- 14.7
- Forward P/E
- 9.4
- Dividend yield
- 3.9%
- 52-week range
- $42.85 – $61.70
- 52-week change
- +8.11%
- EPS (trailing)
- $3.17
- Analyst rating
- 2.6 Hold
- Next earnings
- Oct 28, 2026
About GSK plc
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through Commercial Operations and Total R&D segments. The company offers specialty medicines that include oncology, respiratory/immunology, inflammation, and inhaled medicines for HIV, respiratory eosinophildriven diseases, lupus and lupus nephritis, ovarian cancer, and endometrial cancer. It also provides vaccines for Shingles, Meningitis, RSV, Seasonal Influenza, Hepatitis, Diphtheria, Tetanus, Acellular Pertussis, Rotavirus, Pertussis, Polio, Haemophilus, Invasive Diseases, Pneumonia, Acute Otitis Media, Measles, Mumps, Rubella and Chickenpox, and Human Papilloma Virus. Additionally, the company offers general medicines for asthma, COPD, bacterial infection, benign prostatic hyperplasia, allergic rhinitis, and inflammatory skin conditions. It also focuses on the discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases.
Headquarters: London, United Kingdom · 66,841 employees · gsk.com